Biote Corp. (NASDAQ: BTMD) has appointed Robert Peterson as its new Chief Financial Officer, effective January 8, 2024. In his role, Mr. Peterson will oversee Biote's finance operations, including accounting, financial planning and analysis, financial reporting, internal audit, tax, treasury, and investor relations. He brings 15 years of experience in the health and wellness industry, along with a background in public companies.
Robert Peterson succeeds Samar Kamdar, who is stepping down to pursue other opportunities but will stay on as an advisor during the transition period. The company clarified that Mr. Kamdar's departure is unrelated to any financial issues or disagreements.
Before joining Biote, Mr. Peterson served as the Executive Vice President, Chief Financial Officer of Virbac Corporation, a subsidiary of Virbac S.A., a global veterinary pharmaceutical and wellness company. He also gained eight years of experience at Alcon Laboratories/Novartis Eye Care, holding various roles, including Global Head of Business Planning and Analysis and Finance Manager Investor Relations.
Terry Weber, Biote's Chief Executive Officer, expressed confidence in Mr. Peterson's abilities, stating that his experience and expertise in financial planning and analysis will contribute to the company's strategic vision of becoming a leading provider of evidence-based therapeutic wellness solutions. Weber also acknowledged Samar Kamdar's contributions and wished him success in future endeavors.
Mr. Peterson expressed his enthusiasm about joining Biote during a crucial period of expansion into the therapeutic wellness market. He looks forward to collaborating with the management team to maximize growth opportunities, enhance operating efficiencies, and achieve financial objectives.
